UK markets closed

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
7.24+0.12 (+1.69%)
As of 12:57PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close7.12
Open7.25
Bid7.21 x 800
Ask7.27 x 1000
Day's range7.01 - 7.27
52-week range5.61 - 11.63
Volume4,142
Avg. volume30,419
Market cap463.155M
Beta (5Y monthly)0.39
PE ratio (TTM)19.57
EPS (TTM)0.37
Earnings date02 Mar 2022 - 07 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est23.43
  • Globe Newswire

    Amryt Announces New Patent for Mycapssa®

    Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, November 30, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its product Mycapssa® (octreotide). Mycapssa®The USPTO has issued to Amryt US Patent No. 11,510,963, with claims related to the Mycapssa® product. This patent will expire in February 2036. With the

  • Globe Newswire

    Amryt Reports Q3 2022 Financial and Operational Results

    Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expect

  • Globe Newswire

    Amryt Supports Acromegaly Awareness Day 2022

    Amryt Supports Acromegaly Awareness Day 2022 DUBLIN, Ireland, and Boston MA, October 31, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces its support for Acromegaly Awareness Day 2022 which is taking place on November 1, 2022. Dr Joe Wiley, CEO of Amryt Pharma, commented: “Acromegaly is a rare endocrine disorder caused by an abundance of growth hormone t